Spyre Therapeutics, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +3.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.71 | $-0.36 | +49.3% | Beat | |
| Q1 FY26 | $-0.66 | $-0.74 | -12.1% | Miss | |
| Q3 FY25 | not reported | $-0.15 | not reported | not reported | |
| Q2 FY25 | $-0.73 | $-0.49 | +32.9% | Beat | |
| Q1 FY25 | $-0.76 | $-0.74 | +2.6% | Beat | |
| Q4 FY24 | $-1.10 | $-0.81 | +26.4% | Beat | |
| Q3 FY24 | $-0.80 | $-1.36 | -70.0% | Miss | |
| Q2 FY24 | $-0.90 | $-0.86 | +4.4% | Beat | |
| Q1 FY24 | $-0.90 | $-1.20 | -33.3% | Miss | |
| Q4 FY23 | not reported | $-2.28 | not reported | not reported | |
| Q3 FY23 | not reported | $-3.43 | not reported | not reported | |
| Q2 FY23 | not reported | $-1.66 | not reported | not reported |
Back to SYRE overview · SYRE holders · SYRE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.